Study finds risankizumab to be noninferior and superior to ustekinumab for Crohn’s disease treatment.
- Risankizumab was found to be noninferior to ustekinumab for clinical remission at week 24 in patients with moderate-to-severe Crohn’s disease.
- Risankizumab was superior to ustekinumab for endoscopic remission at week 48 in the same patient population.
- An open-label randomized controlled trial demonstrated that risankizumab had higher efficacy compared to ustekinumab, aligning with previous findings in patients with plaque psoriasis.
- Both primary endpoints (clinical remission at week 24 and endoscopic remission at week 48) were met in the study.
- The incidence of adverse events was similar between the risankizumab and ustekinumab groups, with no significant difference noted.
Source link
Gastroenterology,Oncology,InternalMedicine